Peenya Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 3.00 Cr
- Paid Up Capital ₹ 2.63 Cr
- Company Age 8 Year, 6 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -7.80%
- Profit Growth -750.69%
- Ebitda -650.19%
- Net Worth -188.07%
- Total Assets -13.57%
About Peenya Pharmaceuticals
Peenya Pharmaceuticals Private Limited (PPPL) is a Private Limited Indian Non-Government Company incorporated in India on 09 July 2016 (Eight years and six months 27 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Travel And Hospitality Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.00 Cr and a paid-up capital of Rs 2.63 Cr, as per Ministry of Corporate Affairs (MCA) records.
Asha Thontadarya and Arun Mathad serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999KA2016PTC094826
-
Company No.
094826
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
09 Jul 2016
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Peenya Pharmaceuticals?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Asha Thontadarya
|
Director | 27-Mar-2023 | Current |
|
Arun Mathad
|
Director | 09-Jul-2016 | Current |
Financial Performance of Peenya Pharmaceuticals.
Peenya Pharmaceuticals Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 7.8% decrease. The company also saw a substantial fall in profitability, with a 750.69% decrease in profit. The company's net worth observed a substantial decline by a decrease of 188.07%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Peenya Pharmaceuticals?
In 2023, Peenya Pharmaceuticals had a promoter holding of 44.00% and a public holding of 56.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Celest Pharma Labs Private LimitedAsha Thontadarya and Arun Mathad are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Peenya Pharmaceuticals?
Peenya Pharmaceuticals has a workforce of 22 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Peenya Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Peenya Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
